EADV: Celgene helps to raise awareness of psoriasis burden and presents new Otezla data

14 October 2014

US biotech company Celgene (Nasdaq: CELG) took a practical approach to raising awareness of psoriasis and psoriatic arthritis (PA) during the annual meeting of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, the Netherlands, last week.

The company invited representatives from patient organizations and media outlets for a workshop chaired by UK-based GP and TV presenter Dawn Harper. The attendees were treated to three short scenes, performed by talented actors, to demonstrate the true cost of living with psoriasis and PA. The scenes focused on father and daughter Daniel and Maria, who discussed the burden of their disease, from being unable to unscrew a bottle and being too tired to play sport because of PA, to Maria’s embarrassment over her skin when swimming or choosing clothes.

Current landscape

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK